Oral Dydrogesterone as Luteal Phase Support in Natural Cycle FET

Launched by THE UNIVERSITY OF HONG KONG · Feb 28, 2019

Keywords

ClinConnect Summary

This clinical trial is studying whether taking a medication called oral dydrogesterone can help increase the chances of live births in women undergoing a specific fertility treatment known as natural frozen embryo transfer (FET). The trial is looking for women under 43 years old who are preparing to have embryos transferred after thawing them. Participants will be randomly assigned to either receive dydrogesterone or not, and neither they nor the researchers will know who is in which group to keep the study fair.

To be eligible, women must be under 43 years old and not require hormonal treatments or use donor eggs or embryos. Participants can expect to be involved in a study that aims to improve fertility outcomes, and they will be closely monitored throughout the process. This trial is currently recruiting participants, so if you meet the criteria and are interested, this could be a valuable opportunity to help advance fertility treatments.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Age of women \<43 years at the time of stimulated IVF
• • Replacing early cleavage embryos or blastocysts after thawing
• Exclusion Criteria:
• • Requiring hormonal replacement cycles
• • Use of donor oocytes or embryos
• • Undergoing preimplantation genetic testing
• • Presence of hydrosalpinx not corrected surgically prior to FET
• • Refusal to join the study